11 November 2019
What Do We Know About the Gut Microbiota in Parkinson's Disease?
Results of studies investigating the gut microbiome playing a role in the development of Parkinson's disease (PD) are compared to provide recommendations to improve patient outcomes. This review is published in the open access JPD special issue on "The Gut-Brain Axis in Parkinson's Disease".
8 November 2019
Researchers Report New Insights Into Parkinson's Disease-Related Mortality
Amsterdam, NL – By following a group of newly diagnosed patients with Parkinson's disease (PD) for a decade or more, researchers have been able to identify several factors never before reported that appear to be associated with higher mortality rates in PD patients compared to the general populat
7 November 2019
Where Does Parkinson’s Disease Start? In the Brain or Gut? Or Both?
Does Parkinson's disease (PD) start in the brain or the gut? This review is published in the open access JPD special issue on "The Gut-Brain Axis in Parkinson's Disease".
ADX48621 for the Treatment of Levodopa Induced Dyskinesia in Patients With Parkinson’s Disease
Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, 4-way Crossover, Dose-finding Study of Eltoprazine Safety, Tolerability, and Efficacy in the Treatment of Levodopa-induced Dyskinesia in Patients With Parkinson’s Disease
Buspirone Treatment of Iatrogenic Dyskinesias in Advanced Parkinson’s Disease. Multicenter, International, Placebo-controlled, Randomised, Double-Blind Trial
Buspirone, in Combination With Amantadine, for the Treatment of Levodopa-induced Dyskinesia
A Study in Parkinson’s Disease in paTients with mOderate to seveRe dyskInesiA (ASTORIA)
Efficacy and Tolerability of IRL790 in Parkinson’s Disease Dyskinesia
A 14-week, Double-blind, Randomized, Three-arm, Parallel-Group Study to Assess the Efficacy and Safety of Two Doses of Pridopidine Versus Placebo for the Treatment of Levodopa-induced Dyskinesia in Patients With Parkinson’s Disease (gLIDe)
25 September 2019
How and Why Does Parkinson’s Disease Affect Women and Men Differently?
Amsterdam, NL – There is growing evidence that Parkinson's disease (PD) affects women and men differently.
22 August 2019
Fatigue in Parkinson’s Disease Is Associated with Lower Diastolic Blood Pressure
Amsterdam, NL – Fatigue is a common debilitating symptom in Parkinson's disease (PD).
12 June 2019
2019 World Parkinson’s Disease Congress Abstracts are Openly Available in JPD
JPD is proud to host the abstracts of the 2019 World Parkinson’s Congress, which took place this month in Kyoto, Japan.
To view the openly available abstracts, click the visual below or go here.
A Study to Assess the Safety and Efficacy of the Gastric-retentive AP-CD/LD in Advanced Parkinson’s Patients (Accordance)
A Phase 1 Open-Label Dose Escalation Safety Study of Convection Enhanced Delivery (CED) of Adeno-Associated Virus Encoding Glial Cell Line-Derived Neurotrophic Factor (AAV2-GDNF) in Subjects with Advanced Parkinson’s Disease
Study of OXB-102 (AXO-Lenti-PD) in patients with idiopathic Parkinson’s Disease (SUNRISE-PD)
VY-AADC02 for Parkinson’s Disease with motor fluctuations
A Phase 1/2 Study of Intra-putaminal Infusion of Adeno-Associated Virus Encoding Human Aromatic L-Amino Acid Decarboxylase in Subjects with Parkinson’s Disease
Nilotinib in Parkinson’s Disease (NILO-PD)
Impact of Nilotinib on Safety, Tolerability, Pharmacokinetics and Biomarkers in Parkinson’s Disease (PD Nilotinib)
A Phase 1, Randomized, Double-Blind, Single Ascending Dose Trial of the Safety, Tolerability and Pharmacokinetics of NPT200-11 in Healthy Subjects
Phenylbutyrate Response as a Biomarker for Alpha-synuclein Clearance from the Brain
A study to evaluate the efficacy of Prasinezumab (RO7046015/PRX002) in participants with early Parkinson’s Disease (PASADENA)
Interventional, Randomized, Double-blind, Sequential-group, Placebo-controlled, Single-ascending-dose Study Investigating the Safety, Tolerability and Pharmacokinetic and Pharmacodynamic Properties of Lu AF82422 in Healthy Non-Japanese and Japanese Subjec
Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Participants with Parkinson’s Disease (SPARK)
A Randomized, Double-blind, Placebo-controlled Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of MEDI1341 in Healthy Male and Female Volunteers
Study Assessing Tolerability and Safety of AFFITOPE® PD03A in Patients with Early Parkinson’s Disease (AFF011)
Phase 1 study series of PD01 in early Parkinson’s Disease
A Phase 3 study of isradipine as a disease modifying agent in patients with early Parkinson’s disease (STEADY-PD III)
27 February 2019
New Treatment Offers Potentially Promising Results for the Possibility of Slowing, Stopping, or Even Reversing Parkinson's Disease
Amsterdam, NL – A pioneering clinical trials program that delivered an experimental treatment directly to the brain offers hope that it may be possible to restore the cells damaged in Parkinson's disease.
14 February 2019
Can We Repair the Brain? The Promise of Stem Cell Technologies for Treating Parkinson's Disease
Amsterdam, NL – Cell replacement may play an increasing role in alleviating the motor symptoms of Parkinson's disease in future. Writing in a special open access special supplement to the Journal of Parkinson's Disease, experts describe how newly developed stem cell technologies could be used to treat the disease and discuss the great promise, as well as the significant challenges, of stem cell treatment.
12 February 2019
The Search for the Holy Grail: Promising Strategies for Slowing, Stopping, or Reversing Parkinson's Disease
Amsterdam, NL – Understanding of the processes involved in Parkinson's disease (PD) degeneration has vastly improved over the last 20 years. In this insightful review published in an open access special supplement to the Journal of Parkinson's Disease, experts consider which of the existing strategies to slow down or stop the degenerative processes of PD are most likely to be successful over the next 20 years.
8 February 2019
Launch of Clinical Trial Highlights in JPD
We are pleased to announce, as of the first issue of JPD Volume 9 (2019), a new section dedicated to Clinical Trials Highlights.
7 February 2019
The Involvement of the Gut in Parkinson’s Disease: Hype or Hope?
Amsterdam, NL – There is growing evidence that at least in some patients with Parkinson's disease, the disease may begin in the gut. Writing in an open access special supplement to the Journal of Parkinson's Disease, experts explore the last two decades of research about the gut-brain axis in PD and look ahead at the possible development and impact of these research areas in the next two decades.
5 February 2019
Experts Propose Revising the Criteria for Diagnosis of Parkinson's Disease with a View Towards Earlier Treatment and Prevention
Amsterdam, NL – In the past 25 years, it has become clear that some symptoms of Parkinson's disease occur decades before the development of motor symptoms and clinical diagnosis, and that monitoring these emerging symptoms may provide important insights into the origin and development of the disease.
31 January 2019
The Search for Environmental Causes of Parkinson's Disease Moves Forward
Amsterdam, NL – Environmental factors are widely believed to play a key role in the development of Parkinson's disease (PD), but little is known about specific environmental triggers. Writing in a supplement to the Journal of Parkinson's Disease, scientists review novel research hypotheses and approaches that may help better define the role of environment in the development of PD, especially before a diagnosis can be made based on the characteristic motor dysfunction for which PD is known.
29 January 2019
Emerging Evidence of an Impending Parkinson’s Disease Pandemic Identified
Amsterdam, NL – For most of human history Parkinson's disease (PD) has been a rare disorder. However, demography and the by-products of industrialization are now contributing to an impending a Parkinson’s pandemic, according to experts writing in a supplement to JPD.
Pages
